Evaluation of tumor and patient characteristics will be critical to define if there are those who may benefit from N-803 plus pembrolizumab.Clinical trial information: NCT05096663.John M. WrangleMedical University of South Carolina, Charleston, SCMary Weber Redman...
The lower IL-15 activity of these fusion molecules may enhance the clinical utility of this type of molecule in general. It has been shown that one of the determining factors of ADCC effectiveness of an antibody is concentration, which affects its bound density on the target cells (22). The...
In summary, this first-in-human clinical trial demonstrates the safety of ALT-803, with an excellent safety profile, and provides evidence of activity in patients who have relapsed after allo-HCT. SQ administration of this immunostimulatory agent resulted in more sustained drug levels and better bi...
Based on preclinical non-human primate and early phase clinical trial data, the cytokine IL-15 can potently increase NK cell numbers to augment immunotherapy [23], [24], [25], [26]. Endogenous IL-15 binds to IL-15Rα (on or shed by monocytes and dendritic cells) to form a natural ...
This phase Ib clinical trial evaluated the safety and toleraibility of ALT-803, an IL-15 superagonist, plus BCG in patients with BCG-naive NMIBC. Methods: This is a Phase Ib trial using the 3+3 design to evaluate intravesical ALT-803 plus BCG 50 mg in BCG-naive NMIBC patients, who ...